Journal of Aerosol Medicine and Pulmonary Drug Delivery,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 9, 2024
Approved
drug
products
may
be
subject
to
change(s)
for
a
variety
of
reasons.
The
changes
include,
but
are
not
limited
to,
increase
in
batch
size,
alteration
the
product
constituent(s),
improvement
manufacturing
process,
and
shift
sites.
extent
pharmaceutical
testing
regulatory
pathway
timely
implementation
any
change
approved
and/or
process
depends
upon
nature
change.
U.S.
Food
Drug
Administration
(FDA)
has
published
guidelines
that
outline
its
expectations
Scale-Up
Postapproval
Changes
(SUPAC)
solid
oral
immediate
modified
release
(MR)
products,
semisolid
formulations.
However,
date,
no
such
have
been
issued
address
SUPAC
orally
inhaled
(OIDPs),
this
article
represents
seminal
contribution
direction.
It
is
hoped
it
will
inspire
contributions
from
relevant
multidisciplinary
experts
industry
agency
accomplishing
formal
OIDP
SUPAC.
OIDPs
complex
drug-device
combination
products.
Therefore,
conceptualization
these
warrants
consideration
effect
individual
components
(drug
substance,
formulation,
device)
as
well
compound
single
or
multiple
on
performance,
safety
efficacy.
This
provides
discussion
scientific
aspects
bases
development
OIDPs,
attempts
considerations
applicable
addressing
issues
related
context
human
drugs.
authors'
statements
should
viewed
recommendations
agency,
would
determined
case-by-case
evaluation
by
authorities.
Materials Today Bio,
Journal Year:
2024,
Volume and Issue:
25, P. 100966 - 100966
Published: Jan. 22, 2024
Pulmonary
drug
delivery
has
the
advantages
of
being
rapid,
efficient,
and
well-targeted,
with
few
systemic
side
effects.
In
addition,
it
is
non-invasive
good
patient
compliance,
making
a
highly
promising
mode.
However,
there
have
been
limited
studies
on
via
pulmonary
inhalation
compared
oral
intravenous
modes.
This
paper
summarizes
basic
research
clinical
translation
for
treatment
diseases
provides
insights
into
latest
advances
in
delivery.
The
discusses
processing
methods
delivery,
carriers
(with
focus
various
types
nanoparticles),
devices,
applications
(e.g.,
COVID-19,
inhaled
vaccines,
diagnosis
diseases,
diabetes
mellitus)
an
updated
summary
recent
advances.
Furthermore,
this
describes
progress
lung
expands
use
drugs
other
diseases.
Bioengineering,
Journal Year:
2024,
Volume and Issue:
11(8), P. 788 - 788
Published: Aug. 4, 2024
Nanotechnology
plays
a
pivotal
role
in
the
biomedical
field,
especially
synthesis
and
regulation
of
drug
particle
size.
Reducing
particles
to
micron
or
nanometer
scale
can
enhance
bioavailability.
Supercritical
fluid
technology,
as
green
development
strategy,
is
expected
resolve
challenges
thermal
degradation,
uneven
size,
organic
solvent
residue
faced
by
traditional
methods
such
milling
crystallization.
This
paper
provides
an
insight
into
application
super-stable
homogeneous
intermix
formulating
technology
(SHIFT)
super-table
pure-nanomedicine
formulation
(SPFT)
developed
based
on
supercritical
fluids
for
dispersion
micronization.
These
technologies
significantly
solubility
permeability
hydrophobic
drugs
controlling
size
morphology,
modified
show
excellent
therapeutic
efficacy
treatment
hepatocellular
carcinoma,
pathological
scarring,
corneal
neovascularization,
their
performance
are
highlighted
when
administered
through
multiple
routes
administration.
Overall,
have
opened
efficient
pathway
clinical
development,
which
reduce
side
effects
efficacy.
Asian Journal of Atmospheric Environment,
Journal Year:
2025,
Volume and Issue:
19(1)
Published: Jan. 22, 2025
Abstract
Chronic
obstructive
pulmonary
disease
(COPD)
is
induced
by
inhalation
of
toxic
substances
such
as
cigarettes
and
air
pollution.
Dry
powder
inhalers
(DPIs)
are
the
primary
treatment
for
these
diseases.
However,
they
have
some
problems,
residuals
in
a
capsule
caused
electrostatic
force
before
reaching
human
lungs.
This
study
investigated
particle
tribocharging
mechanism
DPI
using
tandem
differential
mobility
analyzer
(TDMA)
combined
discrete
element
method
computational
fluid
dynamics
(DEM-CFD)
approach.
In
TDMA
experiment,
charging
state
particles
changed
from
negative
to
positive
charge
device
fabricated
3D
printer.
because
particle–particle
collisions
particle–wall
collisions.
numerical
simulation,
occurred
more
frequently
than
Therefore,
change
device.
These
results
suggest
that
between
walls
cause
become
charged,
leading
decrease
their
deposition
deeper
regions
Moreover,
large
turbulence
kinetic
energy
airflow
were
widely
dispersed
optimum
necessary
reduce
aggregation
improve
delivery
efficiency
DPIs
Graphical
Viruses,
Journal Year:
2025,
Volume and Issue:
17(2), P. 252 - 252
Published: Feb. 12, 2025
Inhaled
dry
powder
formulations
of
antiviral
agents
represent
a
novel
and
potentially
transformative
approach
to
managing
respiratory
viral
infections.
Traditional
therapies
in
the
form
tablets
or
capsules
often
face
limitations
terms
therapeutic
activity,
systemic
side
effects,
delayed
onset
action.
Dry
inhalers
(DPIs)
provide
targeted
delivery
system,
ensuring
direct
administration
antivirals
infection
site,
tract,
which
enhance
efficacy
minimize
exposure.
This
review
explores
current
state
inhaled
agents,
their
advantages
over
traditional
routes,
specific
under
development.
We
discuss
benefits
delivery,
such
as
improved
drug
deposition
lungs
reduced
alongside
considerations
related
formulation
preparation.
In
addition,
we
summarize
developed
(published
marketed)
powders
agents.
